Want to see IKT full AI Analyst Report?
Inhibikase Therapeutics (IKT) Income Statement
Inhibikase Therapeutics Income Statement
Last quarter (Q2 2026), Inhibikase Therapeutics's total revenue was $0.00. In Q2, Inhibikase Therapeutics's net income was $-19.59M. See Inhibikase Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 260.50K | $ 123.44K | $ 3.10M | |
| $ 0.00 | $ -26.27K | $ -13.36M | $ 116.72K | $ -8.26M | |
| $ 51.97M | $ 28.56M | $ 6.73M | $ 18.25M | $ 6.51M | |
| Depreciation and Amortization | $ 60.50K | $ 26.27K | $ 177.40K | $ 6.72K | $ 14.77M |
| $ -53.29M | $ -27.49M | $ -18.85M | $ -18.05M | $ 0.00 | |
| $ -51.97M | $ -28.59M | $ -20.09M | $ -18.13M | $ -14.77M | |
| $ 3.72M | $ 1.07M | $ 1.06M | $ 74.45K | $ -19.92K | |
| $ -48.26M | $ -27.52M | $ -19.03M | $ -18.05M | $ -14.79M | |
| $ -48.26M | $ -27.52M | $ -19.03M | $ -18.05M | $ -14.79M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.49 | $ -1.16 | $ -3.57 | $ -4.26 | $ -4.88 |
| Diluted EPS | $ -0.49 | $ -1.16 | $ -3.57 | $ -4.26 | $ -4.88 |
| Weighted Average Shares Outstanding | 98.31M | 23.71M | 5.33M | 4.20M | 3.03M |
| Weighted Average Shares Outstanding (Diluted) | 98.31M | 23.71M | 5.33M | 4.20M | 3.03M |
Currency in USD